Pharmacokinetics and biodistribution of paclitaxel loaded in pegylated solid lipid nanoparticles after intravenous administration

Archives of Pharmacal Research

Volumn 34, Issue 2, 2011, Pages 331-337

  Li, Rihua ^a   Eun, Jae Soon ^a   Lee, Mi Kyung ^a  

^a Woosuk University   (South Korea)

Author keywords

Biodistribution; Paclitaxel; Pegylated solid lipid nanoparticles; Pharmacokinetics

Indexed keywords

NANOPARTICLE; PACLITAXEL; PEGYLATED SOLID LIPID NANOPARTICLE; PHOSPHATIDYLCHOLINE; PHOSPHOLIPID; TRIMYRISTIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG ADMINISTRATION ROUTE; DRUG DISTRIBUTION; HEART; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; KIDNEY; LIVER; LUNG; MALE; NONHUMAN; PARTICLE SIZE; PHARMACOKINETICS; RAT; RETICULOENDOTHELIAL SYSTEM; SINGLE DRUG DOSE; SPLEEN;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DRUG CARRIERS; INJECTIONS, INTRAVENOUS; LIPIDS; MALE; NANOPARTICLES; PACLITAXEL; PARTICLE SIZE; RATS; TISSUE DISTRIBUTION;

EID: 79953302226     PISSN: 02536269     EISSN: 19763786     Source Type: Journal    
DOI: 10.1007/s12272-011-0220-2     Document Type: Article

References (19)

1. Chen, D. B., Yang, T. Z., Lu, W. L., and Zhang, Q., In vitro and in vivo study of two types of long-circulating solid lipid nanoparticles containing paclitaxel. Chem. Pharm. Bull., 49, 1444-1447 (2001).
2. Devalapally, H., Chakilam, A., and Amiji, M. M., Role of nanotechnology in pharmaceutical product development. J. Pharm. Sci., 96, 2547-2565 (2007).
3. Dobrovolskaia, M. A., Aggarwal, P., Hall, J. B., and McNeil, S. E., Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol. Pharm., 5, 487-495 (2008).
4. Fang, J., Nakamura, H., and Maeda, H., The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv. Drug Deliv. Rev. doi:10.1016/j.addr.2010.04.009 (2010).
5. Fundar, A., Cavalli, R., Bargoni, A., Vighetto, D., Zara, G. P., and Gasco, M. R., Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: pharmacokinetics and tissue distribution after i.v. administration to rats. Pharmacol. Res., 42, 337-343 (2000).
6. Gao, Y., Gu, W., Chen, L., Xu, Z., and Li, Y., The role of daidzein-loaded sterically stabilized solid lipid nanoparticles in therapy for cardio-cerebrovascular diseases. Biomaterials, 29, 129-136 (2008).
7. Gelderblom, H., Verweij, J., Nooter, K., and Sparreboom, A., Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur. J. Cancer, 37, 1590-1598 (2001).
8. Lee, M. K., Lim, S. J., and Kim, C. K., Preparation, characterization and in vitro cytotoxicity of paclitaxel-loaded sterically stabilized solid lipid nanoparticles. Biomaterials, 28, 2137-2146 (2007).
9. Nornoo, A. O. and Chow, D. S., Cremophor-free intravenous microemulsions for paclitaxel II. Stability, in vitro release and pharmacokinetics. Int. J. Pharm., 349, 117-123 (2008).
10. Reddy, L. H., Vivek, K., Bakshi, N., and Murthy, R. S., Tamoxifen citrate loaded solid lipid nanoparticles (SLN): preparation, characterization, in vitro drug release, and pharmacokinetic evaluation. Pharm. Dev. Technol., 11, 167-177 (2006).
11. Sanjula, B., Shah, F. M., Javed, A., and Alka, A., Effect of poloxamer 188 on lymphatic uptake of carvedilol-loaded solid lipid nanoparticles for bioavailability enhancement. J. Drug Target., 17, 249-256. (2009).
12. Singla, A. K., Garg, A., and Aggarwal, D., Paclitaxel and its formulations. Int. J. Pharm., 20, 179-192 (2002).
13. Souto, E. B. and Doktorovova, S., Solid lipid nanoparticle formulations: pharmacokinetic and biopharmaceutical aspects in drug delivery. Methods Enzymol., 464, 105-129 (2009).
14. Sparreboom, A., Scripture, C. D., Trieu, V., Williams, P. J., De, T., Yang, A., Beals, B., Figg, W. D., Hawkins, M., and Desai, N., Comparative preclinical and clinical pharmacokinetics of a cremophor-free nanoparticle albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in cremophor (Taxol). Clin. Cancer Res., 11, 4136-4143 (2005).
15. Wall, E. M. and Wani, M. C., Camptothecin and Taxol; discovery to clinic-thirteenth Bruce F. Cain Memorial Award Lecture. Cancer Res., 55, 753-760 (1993).
16. Wang, Y. and Wu, W., In situ evading of phagocytic uptake of stealth solid lipid nanoparticles by mouse peritoneal macrophages. Drug Deliv., 13, 189-192 (2006).
17. Weiss, R. B., Donehower, R. C., Wiernik, P. H., Ohnuma, T., Gralla, R. J., Trump, D. L., Baker, J. R. Jr., Van Echo, D. A., Von Hoff, D. D., and Leyland-Jones, B., Hypersensitivity reactions from taxol. J. Clin. Oncol., 8, 1263-1268 (1990).
18. Yang, S. C., Lu, L. F., Cai, Y., Zhu, J. B., Liang, B. W., and Yang, C. Z., Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J. Control. Release, 59, 299-307 (1999).
19. Zhang, X., Pan, W., Gan, L., Zhu, C., Gan, Y., and Nie, S., Preparation of a dispersible PEGylate nanostructured lipid carriers (NLC) loaded with 10-hydroxycamptothecin by spray-drying. Chem. Pharm. Bull., 56, 1645-1650 (2008).